BIO-RAD LABORATORIES, INC. (BIO) FY2026 YTD Q2 Statement of Cash Flows

Income StatementCash FlowBalance Sheet

Statement of Cash Flows

2026-01-01 to 2026-06-30

Swipe to see the full flow
BIO-RAD LABORATORIES, INC. cash flow reconciliation, Jan 1, 2026 through Jun 30, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Identified asset purchases, sales and maturities are blue in either cash direction. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Cash received from customers → operating reconciliation: $1,242,700,000.00Investment proceeds and miscellaneous receipts, net → operating reconciliation: $49,000,000.00Proceeds from forward foreign exchange contracts, net → operating reconciliation: $17,300,000.00operating reconciliation → Net cash from operating activities: $206,800,000.00operating reconciliation → Cash paid to suppliers and employees: $1,054,600,000.00operating reconciliation → Income tax payments, net: $24,300,000.00operating reconciliation → Interest paid, net: $23,300,000.00Proceeds from Sale of Debt Securities, Available-for-sale → investing reconciliation: $271,900,000.00Proceeds from maturities of marketable securities and investments → investing reconciliation: $39,400,000.00(Payments for) proceeds from acquisitions, net of cash received → investing reconciliation: $1,100,000.00investing reconciliation → Payments for purchases of marketable securities and investments: $410,300,000.00investing reconciliation → Capital expenditures: $62,000,000.00Net cash used in financing activities → financing reconciliation: $71,600,000.00Proceeds from Issuance of Common Stock → financing reconciliation: $7,600,000.00Option Premium Proceeds For Structured Purchases Of Treasury Stock → financing reconciliation: $500,000.00financing reconciliation → Payments for purchases of treasury stock: $79,300,000.00financing reconciliation → Payments on long-term borrowings: $300,000.00financing reconciliation → Tax payments from net share settlement: $100,000.00Net cash used in investing activities → investing reconciliation: $159,900,000.00Exchange-rate effect → Cash sources and uses: $11,300,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $532,200,000.00Net cash from operating activities → Cash sources and uses: $206,800,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $518,800,000.00Cash sources and uses → Net cash used in investing activities: $159,900,000.00Cash sources and uses → Net cash used in financing activities: $71,600,000.00Cash received from customers: $1,242,700,000.00Cash received from customers+$1.24 BCash paid to suppliers and employees: -$1,054,600,000.00Suppliers & employees paid−$1.05 BInterest paid, net: -$23,300,000.00Interest paid, net−$23.30 MIncome tax payments, net: -$24,300,000.00Income tax payments, net−$24.30 MInvestment proceeds and miscellaneous receipts, net: $49,000,000.00Investment income received+$49.00 MProceeds from forward foreign exchange contracts, net: $17,300,000.00Forward FX proceeds, net+$17.30 MNet cash from operating activities: $206,800,000.00Operating cash+$206.80 Moperating reconciliation: $1,309,000,000.00Payments on long-term borrowings: -$300,000.00Long-term debt repaid−$300.00 KProceeds from Issuance of Common Stock: $7,600,000.00Common stock issued+$7.60 MTax payments from net share settlement: -$100,000.00Stock-award tax withholding−$100.00 KPayments for purchases of treasury stock: -$79,300,000.00Common stock repurchases−$79.30 MOption Premium Proceeds For Structured Purchases Of Treasury Stock: $500,000.00Treasury option premium proceeds+$500.00 KNet cash used in financing activities: -$71,600,000.00. Cash required to fund net payments.Financing cash−$71.60 Mfinancing reconciliation: $79,700,000.00Capital expenditures: -$62,000,000.00PP&E purchases−$62.00 MProceeds from dispositions of property, plant and equipment: $0.00(Payments for) proceeds from acquisitions, net of cash received: $1,100,000.00Acquisitions, net of cash+$1.10 MPayments for purchases of marketable securities and investments: -$410,300,000.00Investment purchases−$410.30 MProceeds from Sale of Debt Securities, Available-for-sale: $271,900,000.00AFS securities sales+$271.90 MProceeds from maturities of marketable securities and investments: $39,400,000.00AFS securities maturities+$39.40 MNet cash used in investing activities: -$159,900,000.00. Cash required to fund net payments.Investing cash−$159.90 Minvesting reconciliation: $472,300,000.00Cash sources and uses: $750,300,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $532,200,000.00Beginning cash$532.20 MEnding cash: Cash, cash equivalents, and restricted cash: $518,800,000.00Ending cash$518.80 MExchange-rate effect: $11,300,000.00FX effect+$11.30 MCASH RECONCILIATIONOperatingflowsInvestingflowsFinancingflowsFree cash flow$144.80 MOperating cash − cash spent on PP&ECash flow / Net incomeUnavailableOperating cash flow ÷ net incomeNet cash change−$13.40 MEnding cash − beginning cash
Chart details

BIO-RAD LABORATORIES, INC. cash flow reconciliation, Jan 1, 2026 through Jun 30, 2026

Cash flows for Jan 1, 2026 through Jun 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Dec 31, 2025. Ending cash: Jun 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Dec 31, 2025
532,200,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
206,800,000 US dollars. Net cash provided.
Cash received from customers
1,242,700,000 US dollars
Cash paid to suppliers and employees
negative 1,054,600,000 US dollars
Interest paid, net
negative 23,300,000 US dollars
Income tax payments, net
negative 24,300,000 US dollars
Investment proceeds and miscellaneous receipts, net
49,000,000 US dollars
Proceeds from forward foreign exchange contracts, net
17,300,000 US dollars
Investing activities
negative 159,900,000 US dollars. Net cash used.
Capital expenditures
negative 62,000,000 US dollars
Proceeds from dispositions of property, plant and equipment
0 US dollars
(Payments for) proceeds from acquisitions, net of cash received
1,100,000 US dollars
Payments for purchases of marketable securities and investments
negative 410,300,000 US dollars
Proceeds from Sale of Debt Securities, Available-for-sale
271,900,000 US dollars
Proceeds from maturities of marketable securities and investments
39,400,000 US dollars
Financing activities
negative 71,600,000 US dollars. Net cash used.
Payments on long-term borrowings
negative 300,000 US dollars
Proceeds from Issuance of Common Stock
7,600,000 US dollars
Tax payments from net share settlement
negative 100,000 US dollars
Payments for purchases of treasury stock
negative 79,300,000 US dollars
Option Premium Proceeds For Structured Purchases Of Treasury Stock
500,000 US dollars
Operating adjustment reconciliation
1,309,000,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
79,700,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
472,300,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
11,300,000 US dollars
Ending cash on Jun 30, 2026
518,800,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
750,300,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
negative 13,400,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
Unavailable. Operating cash flow and reconciliation net income for the same period are required.
Operating cash flow
206,800,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
62,000,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
144,800,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: 206,800,000 US dollars minus 62,000,000 US dollars equals 144,800,000 US dollars.
BIO-RAD LABORATORIES, INC. (BIO) FY2026 YTD Q2 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!